Human tissue kallikrein in the treatment of acute ischemic stroke

Research output: Contribution to journalReview article

Michelle Alexander-Curtis, Rick Pauls, Julie Chao, John Volpi, Philip M. Bath, Todd A. Verdoorn

Acute ischemic stroke (AIS) remains a major cause of death and disability throughout the world. The most severe form of stroke results from large vessel occlusion of the major branches of the Circle of Willis. The treatment strategies currently available in western countries for large vessel occlusion involve rapid restoration of blood flow through removal of the offending blood clot using mechanical or pharmacological means (e.g. tissue plasma activator; tPA). This review assesses prospects for a novel pharmacological approach to enhance the availability of the natural enzyme tissue kallikrein (KLK1), an important regulator of local blood flow. KLK1 is responsible for the generation of kinins (bradykinin and kallidin), which promote local vasodilation and long-term vascularization. Moreover, KLK1 has been used clinically as a direct treatment for multiple diseases associated with impaired local blood flow including AIS. A form of human KLK1 isolated from human urine is approved in the People’s Republic of China for subacute treatment of AIS. Here we review the rationale for using KLK1 as an additional pharmacological treatment for AIS by providing the biochemical mechanism as well as the human clinical data that support this approach.

Original languageEnglish (US)
JournalTherapeutic Advances in Neurological Disorders
Volume12
DOIs
StatePublished - Jan 1 2019

Altmetrics

Cite this

Standard

Human tissue kallikrein in the treatment of acute ischemic stroke. / Alexander-Curtis, Michelle; Pauls, Rick; Chao, Julie; Volpi, John; Bath, Philip M.; Verdoorn, Todd A.

In: Therapeutic Advances in Neurological Disorders, Vol. 12, 01.01.2019.

Research output: Contribution to journalReview article

Harvard

Alexander-Curtis, M, Pauls, R, Chao, J, Volpi, J, Bath, PM & Verdoorn, TA 2019, 'Human tissue kallikrein in the treatment of acute ischemic stroke' Therapeutic Advances in Neurological Disorders, vol. 12. https://doi.org/10.1177/1756286418821918

APA

Alexander-Curtis, M., Pauls, R., Chao, J., Volpi, J., Bath, P. M., & Verdoorn, T. A. (2019). Human tissue kallikrein in the treatment of acute ischemic stroke. Therapeutic Advances in Neurological Disorders, 12. https://doi.org/10.1177/1756286418821918

Vancouver

Alexander-Curtis M, Pauls R, Chao J, Volpi J, Bath PM, Verdoorn TA. Human tissue kallikrein in the treatment of acute ischemic stroke. Therapeutic Advances in Neurological Disorders. 2019 Jan 1;12. https://doi.org/10.1177/1756286418821918

Author

Alexander-Curtis, Michelle ; Pauls, Rick ; Chao, Julie ; Volpi, John ; Bath, Philip M. ; Verdoorn, Todd A. / Human tissue kallikrein in the treatment of acute ischemic stroke. In: Therapeutic Advances in Neurological Disorders. 2019 ; Vol. 12.

BibTeX

@article{e426294ff1154e42863af1e3621cb200,
title = "Human tissue kallikrein in the treatment of acute ischemic stroke",
abstract = "Acute ischemic stroke (AIS) remains a major cause of death and disability throughout the world. The most severe form of stroke results from large vessel occlusion of the major branches of the Circle of Willis. The treatment strategies currently available in western countries for large vessel occlusion involve rapid restoration of blood flow through removal of the offending blood clot using mechanical or pharmacological means (e.g. tissue plasma activator; tPA). This review assesses prospects for a novel pharmacological approach to enhance the availability of the natural enzyme tissue kallikrein (KLK1), an important regulator of local blood flow. KLK1 is responsible for the generation of kinins (bradykinin and kallidin), which promote local vasodilation and long-term vascularization. Moreover, KLK1 has been used clinically as a direct treatment for multiple diseases associated with impaired local blood flow including AIS. A form of human KLK1 isolated from human urine is approved in the People’s Republic of China for subacute treatment of AIS. Here we review the rationale for using KLK1 as an additional pharmacological treatment for AIS by providing the biochemical mechanism as well as the human clinical data that support this approach.",
keywords = "acute ischemic stroke, bradykinin, human tissue kallikrein, recombinant KLK1, vasodilation",
author = "Michelle Alexander-Curtis and Rick Pauls and Julie Chao and John Volpi and Bath, {Philip M.} and Verdoorn, {Todd A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1756286418821918",
language = "English (US)",
volume = "12",
journal = "Therapeutic Advances in Neurological Disorders",
issn = "1756-2856",
publisher = "SAGE Publications Ltd",

}

RIS

TY - JOUR

T1 - Human tissue kallikrein in the treatment of acute ischemic stroke

AU - Alexander-Curtis, Michelle

AU - Pauls, Rick

AU - Chao, Julie

AU - Volpi, John

AU - Bath, Philip M.

AU - Verdoorn, Todd A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Acute ischemic stroke (AIS) remains a major cause of death and disability throughout the world. The most severe form of stroke results from large vessel occlusion of the major branches of the Circle of Willis. The treatment strategies currently available in western countries for large vessel occlusion involve rapid restoration of blood flow through removal of the offending blood clot using mechanical or pharmacological means (e.g. tissue plasma activator; tPA). This review assesses prospects for a novel pharmacological approach to enhance the availability of the natural enzyme tissue kallikrein (KLK1), an important regulator of local blood flow. KLK1 is responsible for the generation of kinins (bradykinin and kallidin), which promote local vasodilation and long-term vascularization. Moreover, KLK1 has been used clinically as a direct treatment for multiple diseases associated with impaired local blood flow including AIS. A form of human KLK1 isolated from human urine is approved in the People’s Republic of China for subacute treatment of AIS. Here we review the rationale for using KLK1 as an additional pharmacological treatment for AIS by providing the biochemical mechanism as well as the human clinical data that support this approach.

AB - Acute ischemic stroke (AIS) remains a major cause of death and disability throughout the world. The most severe form of stroke results from large vessel occlusion of the major branches of the Circle of Willis. The treatment strategies currently available in western countries for large vessel occlusion involve rapid restoration of blood flow through removal of the offending blood clot using mechanical or pharmacological means (e.g. tissue plasma activator; tPA). This review assesses prospects for a novel pharmacological approach to enhance the availability of the natural enzyme tissue kallikrein (KLK1), an important regulator of local blood flow. KLK1 is responsible for the generation of kinins (bradykinin and kallidin), which promote local vasodilation and long-term vascularization. Moreover, KLK1 has been used clinically as a direct treatment for multiple diseases associated with impaired local blood flow including AIS. A form of human KLK1 isolated from human urine is approved in the People’s Republic of China for subacute treatment of AIS. Here we review the rationale for using KLK1 as an additional pharmacological treatment for AIS by providing the biochemical mechanism as well as the human clinical data that support this approach.

KW - acute ischemic stroke

KW - bradykinin

KW - human tissue kallikrein

KW - recombinant KLK1

KW - vasodilation

UR - http://www.scopus.com/inward/record.url?scp=85060457446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060457446&partnerID=8YFLogxK

U2 - 10.1177/1756286418821918

DO - 10.1177/1756286418821918

M3 - Review article

VL - 12

JO - Therapeutic Advances in Neurological Disorders

T2 - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

SN - 1756-2856

ER -

ID: 45779820